Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO EBITDA Margin

EBITDA as a percentage of revenue.

Profound Medical Corp.TSX: PRN.TO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -148.4%

EBITDA Margin was -148.4% in Q1 FY2026, up 271.4 pp from a year earlier. On a trailing-twelve-month basis it was -194.3%, up 121.3 pp year over year. Over 3 fiscal years it widened by 145.4 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -102.7% for the fiscal year ending Dec 2026, up from -252.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-148.4%-27.0 pp QoQ
Last fiscal yearDec 2025
-252.8%+48.0 pp YoY
LTMMar 2026
-194.3%+121.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+271.4 pp+434.2 pp+162.8 pp
1 year+48.0 pp+150.1 pp+102.1 pp
3 years+145.4 pp+248.7 pp+103.3 pp
5 years+283.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-252.8%
Year-over-year change
+48.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • PRN.TO's LTM Mar 2026 EBITDA Margin of -194.3% is the lowest of the 5 companies compared; the peer median is 27.9%.
  • Its year-over-year change of +121.3 pp is the highest of 5, against a peer median of +3.2 pp.
  • Over three fiscal years its change of +145.4 pp compares with a peer median of +9.6 pp.
PRN.TO Competitors Peer median
EBITDA Margin for PRN.TO and competitors
Company Period LTM level YoY 3-year change
HLS.TOHLS Therapeutics Inc.LTM Mar 202631.9% +6.2 pp+2.6 pp
XLY.TOAuxly Cannabis Group Inc.LTM Mar 202631.0% +5.0 pp+133.5 pp
DR.TOMedical Facilities CorporationLTM Mar 202624.7% -1.0 pp+10.9 pp
CRRX.TOCareRx CorporationLTM Mar 20268.0% +1.5 pp+8.3 pp
PRN.TOProfound Medical Corp.LTM Mar 2026-194.3% +121.3 pp+145.4 pp
EPRX.TOEupraxia Pharmaceuticals Inc.FY2025— ——
Peer median (excluding PRN.TO) 27.9%+3.2 pp+9.6 pp

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.68M16.38M
Cost of Revenue3.92M3.66M2.82M3.64M4.79M
Gross Profit2.95M3.02M4.38M7.04M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.97M20.96M
Selling, General & Admin17.97M17.93M18.62M23.13M32.61M
Operating Expenses33.24M32.62M33M40.1M53.57M
Depreciation & Amortization1.88M1.6M929K936K569.8K
EBITDA(28.65M)(26.6M)(27M)(32.13M)(41.41M)
EBITDA Margin-416.8%-398.2%-375.0%-300.8%-252.8%
Operating Income(30.29M)(29.6M)(28.62M)(33.06M)(41.98M)
Operating Margin-440.7%-443.1%-397.5%-309.6%-256.3%
Interest Income205K1.06M1.64M1.44M1.09M
Interest Expense67K168.82K770K00
Other Income / Expenses(303K)1.22M200K5.24M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(27.82M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(2K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(27.82M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.12)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.12)(1.43)
Weighted Avg Shares20.46M20.77M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.77M21.18M24.77M30.23M

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.